Elsevier

Urology

Volume 48, Issue 2, August 1996, Pages 326-334
Urology

Basic science
Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy*

https://doi.org/10.1016/S0090-4295(96)00184-7Get rights and content

Abstract

Objectives

To determine the expression of prostate-specific membrane antigen (PSMA) before and after androgen-deprivation therapy and to compare PSMA expression with prostate-specific antigen (PSA) expression.

Methods

We studied specimens from 20 patients with prostate cancer undergoing medical or surgical castration or combination androgen-deprivation therapy in whom matched pretreatment and post-treatment tissue specimens were available and 16 patients in whom only a post-treatment specimen was available. The expression of PSMA and PSA in the tissue specimens was determined by immunoperoxidase staining. The extent of staining was calculated by multiplying the percent of antigen-positive tumor cells by the staining intensity to arrive at a stain index for each biomarker. An in vitro study assessed the concentration of PSMA and PSA in extracts of LNCaP cells cultured in the presence or absence of androgen as determined by immunoassays and Western blot analysis.

Results

PSMA reactivity was found to be increased in 55% (11 of 20) of post-treatment primary tissues and 100% (4 of 4) of post-treatment metastatic specimens. In contrast, PSA expression was found to be decreased in 70% (14 of 20) of post-treatment primary and 100% (4 of 4) of post-treatment metastatic specimens. Neither type of androgen-deprivation treatment nor tissue sensitivity to androgen deprivation appeared to influence degree of biomarker expression. PSMA was found to be downregulated and PSA upregulated when LNCaP cells were cultured in the presence of testosterone or dihydrotestosterone.

Conclusions

The enhanced expression of PSMA in tissues and LNCaP cells after androgen deprivation suggests that PSMA is upregulated in the majority of prostate carcinomas after androgen treatment. The high expression in metastatic tissues strongly suggests that PSMA may be a clinically useful target for antibodyand genetic-directed therapy of prostate cancer that recurs after androgen deprivation. The mechanism whereby androgens suppress the expression of PSMA and the association of PSMA with the development of hormone-independent prostate cancers, will require further study.

References (36)

  • ZelefskyMJ et al.

    Neoadjuvant hormonal therapy improves the therapeutic ratio in patients with bulky prostatic cancer treated with three-dimensional conformai radiation therapy

    Int J Radiat Oncol Biol Phys

    (1994)
  • EisenbergerMA et al.

    Chemotherapy for prostatic carcinoma

    Semin Urol

    (1988)
  • YagodaA et al.

    Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer

    Cancer

    (1993)
  • GrignonD et al.

    Changes in immunohistochemical staining in prostatic adenocarcinoma following diethylstilbestrol therapy

    Prostate

    (1985)
  • MurphyWM et al.

    Pathologic changes associated with androgen deprivation therapy for prostate cancer

    Cancer

    (1991)
  • HoroszewiczJS et al.

    Monoclonal antibodies to a new antigenic marker in epithelial cells and serum of prostatic cancer patients

    Anticancer Res

    (1987)
  • WynantGE et al.

    Immunoscintigraphy of prostatic cancer: preliminary results with 111In-labeled monoclonal antibody 7E11-C5.3 (CYT356)

    Prostate

    (1991)
  • Abdel-NabiH et al.

    Monoclonal antibodies and radioimmunoconjugates in the diagnosis and treatment of prostate cancer

    Semin Urol

    (1992)
  • Cited by (0)

    *

    This study was supported in part by a grant from the Cytogen Corporation, Princeton, New Jersey.

    View full text